Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday

Posted on by

Webcasted Conference Call on Friday, October 27, 2023 at 14.00 CET STOCKHOLM, Oct. 25, 2023 /PRNewswire/ — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today the company…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.